Trial reportAmerican journal of hematology2020
Enhancing the R-ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells.
Trial report in American journal of hematology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Circulating plasma cells as a predictive biomarker in Multiple myeloma: an updated systematic review and meta-analysis.Annals of medicine · 2024Pooled it
- Cell-free DNA for the detection of emerging treatment failure in relapsed/ refractory multiple myeloma.Leukemia · 2022Trial
- Phenotypic evolution of circulating plasma cells from early precursor stages to multiple myeloma.Haematologica · 2026Article
- Review
- Enhanced Detection of Multiple Myeloma Cells by Next-Generation Flow Cytometry Following Density Gradient Medium Separation.European journal of haematology · 2026Article
- Distinct immunophenotypic profiles of circulating tumor plasma cells in MGUS and smoldering multiple myeloma.International journal of hematology · 2026Article
- An odyssey of monoclonal gammopathies: focusing on precursors and the progression from MGUS and SMM to multiple Myeloma, with a brief overview of novel therapeutic strategies.Clinical and experimental medicine · 2026Review
- Navigating the evolving management of smoldering multiple myeloma.HemaSphere · 2026Review
- Defining High-Risk Disease Biology in Multiple Myeloma: A Narrative Review.Blood and lymphatic cancer : targets and therapy · 2026Review
- Current risk stratification and staging of multiple myeloma and related clonal plasma cell disorders.Leukemia · 2025Review
- Machine learning risk stratification strategy for multiple myeloma: Insights from the EMN-HARMONY Alliance platform.HemaSphere · 2025Article
- [Prognostic value of circulating plasma cell in newly diagnosed multiple myeloma treated with bortezomib, lenalidomide, and dexamethasone].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Article
- SWIFT-seq enables comprehensive single-cell transcriptomic profiling of circulating tumor cells in multiple myeloma and its precursors.Nature cancer · 2025Article
- Article
- Immunophenotypic characteristics and prognostic value of peripheral blood circulating plasma cells in patients with newly diagnosed multiple myeloma.Journal of medical biochemistry · 2025Article
- The ratio of brain to liver glucose activity and disease activity in multiple myeloma.Blood cancer journal · 2025Article
- Circulating plasma cells: from basic mechanisms to clinical applications.Frontiers in immunology · 2025Review
- Refining High-Risk Multiple Myeloma: Advancements in Genomic, Clinical, and Prognostic Criteria.Mediterranean journal of hematology and infectious diseases · 2025Review
- A review on pathobiology of circulating tumour plasma cells: The sine qua non of poor prognosis in plasma cell neoplasms.Oncology research · 2025Review
- R2-ISS staging combined with circulating plasma cells improves risk stratification for newly diagnosed multiple myeloma: a single-center real-world study.Annals of hematology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
Abstract
Our prior studies identified the prognostic significance of quantifying cPCs by multiparametric flow cytometry (MFC) in newly diagnosed multiple myeloma (NDMM) patients. We evaluated if a similar quantification of cPCs could add prognostic value to the current R-ISS classification of 556 consecutive NDMM patients seen at the Mayo Clinic, Rochester from 2009 to 2017. Those patients that had ≥5 cPCs/μL and either R-ISS stage I or stage II disease were re-classified as R-ISS IIB stage for the purposes of this study. The median time to next therapy (TTNT) and overall survival (OS) for patients with ≥5 cPCs/μL at diagnosis was as follows: R-ISS I (N = 110) - 40 months and not reached; R-ISS II (N = 69) - 30 and 72 months; R-ISS IIB (N = 96) - 21 and 45 months and R-ISS III (N = 281) - 20 and 47 months respectively. Finally, ≥ 5 cPCs/μL retained its adverse prognostic significance in a multivariable model for TTNT and OS. Hence, quantifying cPCs by MFC can potentially enhance the R-ISS classification of a subset of NDMM patients with stage I and II disease by identifying those patients with a worse than expected survival outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.